Oxford Immunotec Reports First Quarter 2017 Financial Results
First quarter revenue of $21.5 million, an increase of 26% compared to prior year period First quarter Tuberculosis revenue of $18.5 million, an increase of 8% compared to prior year period First quarter Tick-borne disease and other revenue of $3.0 million …